Teladoc Health (NYSE:TDOC) Reaches New 52-Week High – Time to Buy?

Shares of Teladoc Health, Inc. (NYSE:TDOC) reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $9.85 and last traded at $9.6850, with a volume of 1721331 shares trading hands. The stock had previously closed at $9.27.

Analysts Set New Price Targets

A number of brokerages recently issued reports on TDOC. Barclays reduced their price target on Teladoc Health from $8.50 to $7.00 and set an “equal weight” rating on the stock in a report on Thursday, March 26th. Weiss Ratings raised Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Bank of America boosted their price objective on shares of Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Finally, Citigroup raised their target price on shares of Teladoc Health from $6.00 to $7.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 5th. Five equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $7.67.

Teladoc Health Stock Performance

The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.72 and a current ratio of 2.80. The business’s 50-day moving average is $7.65 and its 200-day moving average is $6.39. The company has a market capitalization of $1.76 billion, a PE ratio of -10.06 and a beta of 2.10.

Teladoc Health (NYSE:TDOC) last announced its earnings results on Wednesday, April 29th. The health services provider reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.01). Teladoc Health had a negative net margin of 6.81% and a negative return on equity of 11.45%. The business had revenue of $613.85 million for the quarter, compared to the consensus estimate of $611.04 million. During the same period in the prior year, the business posted ($0.53) EPS. Teladoc Health’s revenue for the quarter was down 2.5% on a year-over-year basis. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. On average, research analysts anticipate that Teladoc Health, Inc. will post -0.92 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Carlos Nueno sold 6,196 shares of the stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total transaction of $47,275.48. Following the sale, the insider directly owned 57,671 shares of the company’s stock, valued at approximately $440,029.73. This represents a 9.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Adam C. Vandervoort sold 7,906 shares of Teladoc Health stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total transaction of $60,322.78. Following the completion of the transaction, the insider directly owned 110,261 shares of the company’s stock, valued at $841,291.43. This trade represents a 6.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 39,195 shares of company stock worth $299,058 in the last 90 days. 0.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Teladoc Health

Several institutional investors have recently modified their holdings of TDOC. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Teladoc Health by 2.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 193,714 shares of the health services provider’s stock valued at $1,542,000 after purchasing an additional 5,235 shares during the period. NewEdge Advisors LLC lifted its stake in shares of Teladoc Health by 1,278.7% in the 1st quarter. NewEdge Advisors LLC now owns 11,305 shares of the health services provider’s stock worth $90,000 after purchasing an additional 10,485 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Teladoc Health by 5.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 447,992 shares of the health services provider’s stock worth $3,566,000 after buying an additional 24,124 shares during the last quarter. Acadian Asset Management LLC bought a new stake in Teladoc Health during the first quarter valued at approximately $615,000. Finally, Envestnet Asset Management Inc. purchased a new stake in Teladoc Health during the second quarter valued at approximately $89,000. 76.82% of the stock is owned by hedge funds and other institutional investors.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.